7-imidazol-1-yl-heptylamine | 68887-60-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 7-imidazol-1-yl-heptylamine
• 英文别名: 1-(7-aminoheptyl)imidazole；1-(7-Aminoheptyl)imidazol；1H-Imidazole-1-heptanamine；7-imidazol-1-ylheptan-1-amine
• CAS: 68887-60-5
• 化学式: C₁₀H₁₉N₃
• 分子量: 181.281
• InChiKey: OAZGKZQQCZLBNT-UHFFFAOYSA-N

物化性质

• 沸点：
  339.9±25.0 °C(Predicted)
• 密度：
  1.02±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-imidazol-1-yl-heptylamine 在 氢氧化钾 、 乙醇 作用下， 以 二甲基亚砜 为溶剂， 反应 5.0h， 生成 6-Chloro-3-(7-imidazol-1-yl-heptyl)-1H-quinazoline-2,4-dione
  参考文献：
  名称：

  Thromboxane synthetase inhibitors and antihypertensive agents. 4. N-[(1H-imidazol-1-yl)alkyl] derivatives of quinazoline-2,4(1H,3H)-diones, quinazolin-4(3H)-ones, and 1,2,3-benzotriazin-4(3H)-ones

  摘要：

  The quinazolinedione, quinazolinone, and 1,2,3-benzotriazinone title compounds were prepared as analogues of N-[(1H-imidazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones which were the subject of a previous report from our laboratories. These compounds were evaluated as thromboxane (TX) synthetase inhibitors and as antihypertensive agents. While each series of compounds had activity both as TX synthetase inhibitors and as antihypertensives, the best compounds were N-[(1H-imidazol-1-yl)alkyl]quinazoline-2,4(1H,3H]-diones (V). In general these compounds were all selective enzyme inhibitors at least equipotent with the standard dazoxiben. These compounds were also very active antihypertensive agents as determined in SHR. The SAR is discussed for both types of activity. Compound 20a was further evaluated for TX formation inhibiting properties in several other platelet types both in vitro and ex vivo and is between 100 and 1000 times more potent than dazoxiben.

  DOI：

  10.1021/jm00395a016
• 作为产物：
  描述：

  7-(1H-imidazol-1-yl)heptanenitrile 以 甲苯 为溶剂， 以to produce 7-(1H-imidazol-1-yl)heptan-1-amine as a yellow oil (12.50 g, 95% yield)的产率得到7-imidazol-1-yl-heptylamine
  参考文献：
  名称：

  POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS

  摘要：

  本发明提供了交联胺聚合物，可以有效地结合和清除胆汁酸从胃肠道中。这些胆酸结合聚合物或其制药组合物可以用于治疗各种疾病，包括高胆固醇血症，糖尿病，瘙痒，肠易激综合征-腹泻（IBS-D），胆酸吸收不良等。

  公开号：

  US20130189215A1
• 作为试剂：
  描述：

  2-(4-(1H-imidazol-1-yl)butyl)isoindoline-1,3-dione 、 一水合肼 、 盐酸 在 potassium carbonate 、 1H-咪唑-1-丁胺 、 二氯甲烷 、 2-[ω-(1H-imidazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-dione 、 5-(1H-imidazol-1-yl)pentanamine 、 6-(1H-imidazol-1-yl)hexanamine 、 7-imidazol-1-yl-heptylamine 、 8-(1H-咪唑-1-基)辛烷-1-胺 作用下， 以 乙醇 为溶剂， 反应 5.0h， 生成 1H-咪唑-1-丁胺
  参考文献：
  名称：

  N-(Substituted phenyl)-N'-[(1H-imidazol-1-yl) and

  摘要：

  这句话的中文翻译如下： N-(取代苯基)-N'-[(1H-咪唑-1-基)和(1H-1,2,4-三唑-1-基)烷基]脲是抑制血栓素合酶酶的抑制剂。

  公开号：

  US04576957A1

文献信息

• Inhibiton of thromboxane synthetase with 1-substituted imidazole
  申请人：Ono Pharmaceutical Co., Ltd.

  公开号：US04320134A1

  公开（公告）日：1982-03-16

  The imidazole compounds of the general formula (I): ##STR1## wherein Y is a carboxyl group, a hydroxymethyl group, an N-di or -mono alkyl substituted or unsubstituted carbamoyl group, a cyano group, or an N-di or -mono alkyl substituted or unsubstituted aminomethyl group, and n is an integer of 3 to 20; and pharmaceutically acceptable salts thereof. These compounds have a strong inhibitory effect on thromboxane synthetase from rabbit platelet microsomes, and are useful as therapeutically active agents for inflammation, hypertension, thrombus, cerebral apoplexy and asthma.

  通式（I）的咪唑化合物：其中Y是羧基、羟甲基基团、N-二烷基或-单烷基取代或未取代的氨甲酰基团、氰基，或N-二烷基或-单烷基取代或未取代的氨甲基基团，n为3至20的整数；和其药学上可接受的盐。这些化合物对兔血小板微粒体中的血栓素合成酶具有强烈的抑制作用，并可用作治疗活性剂，治疗炎症、高血压、血栓、脑卒中和哮喘。
• Omega-((hetero)alkyl)benz(cd)-indol-2-amines
  申请人：American Cyanamid Company

  公开号：US05081131A1

  公开（公告）日：1992-01-14

  Omega-((hetero)alkyl)benz(cd)indol-2-amines useful in inhibition of thromboxane synthetase and in treatment of hypertension in warm-blooded animals are disclosed.

  本发明揭示了Omega-((hetero)烷基)苯并(cd)吲哚-2-胺，其在抑制血栓素合成酶和治疗温血动物的高血压方面具有用途。
• Thromboxane synthetase enzyme inhibiting N-[(1H-imidazol-1-yl) and
  申请人：American Cyanamid Company

  公开号：US04555519A1

  公开（公告）日：1985-11-26

  This invention concerns novel N-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]pyridinecarboxamides which are useful as inhibitors of thromboxane synthetase and/or as hypotensive agents in the treatment of hypertension and myocardial ischemia.

  本发明涉及一种新型N-[(1H-咪唑-1-基)和(1H-1,2,4-三唑-1-基)烷基]吡啶-羧酰胺，其可用作抑制血栓素合酶和/或治疗高血压和心肌缺血的降压剂。
• N-[(1H-imidazol-1-yl)alkyl]-1H-indolecarboxamides useful as thromboxane
  申请人：American Cyanamid Company

  公开号：US04619941A1

  公开（公告）日：1986-10-28

  This invention discloses novel N-[(1H-imidazol-1-yl)alkyl]-1H-indolecarboxamides which are useful as inhibitors of thromboxane synthetase and/or as antihypertensive agents in the treatment of hypertension and myocardial ischemia.

  本发明揭示了一种新型的N-[(1H-咪唑-1-基)烷基]-1H-吲哚羧酰胺，可用作血栓素合酶抑制剂和/或抗高血压剂，用于治疗高血压和心肌缺血。
• Substituted N-(omega-(1H-imidazol-1-yl)alkyl)) amides
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0127727A2

  公开（公告）日：1984-12-12

  This disclosure describes novel N-[ω-(1H- imidazol-I-yl)alkyl]amides which possess the property of inhibiting the enzyme thromboxane synthetase.

  本公开介绍了具有抑制血栓素合成酶特性的新型 N-[ω-(1H-咪唑-I-基)烷基]酰胺。